Adrenoleukodystrophy Market is Expected to Witness Significant Growth by 2036 Owing to the Emergence of Gene and Metabolic-targeted Therapies | DelveInsight

The market dynamics for Adrenoleukodystrophy (ALD) are witnessing steady growth driven by the increasing adoption of newborn screening programs, growing awareness regarding rare neurodegenerative disorders, advancements in gene therapy approaches, and rising focus on disease-modifying treatments. Additionally, the launch of emerging therapies such as Leriglitazone (MIN-102) (Minoryx Therapeutics and Neuraxpharm), VK0214 (Viking Therapeutics), PXL065 (Poxel), and others will further fuel the market.

DelveInsight, a leading market research firm, announces the release of its latest report, "DelveInsight's Adrenoleukodystrophy Market Insights, Epidemiology, and Market Forecast 2036." This comprehensive report provides an in-depth understanding of Adrenoleukodystrophy, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Adrenoleukodystrophy Market

*
The market size for Adrenoleukodystrophy in the leading markets is expected to grow significantly by 2036.

*
The United States accounted for the highest Adrenoleukodystrophy treatment market size in 7MM in 2025, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan.

*
DelveInsight's analysis indicates that the total prevalent cases of ALD in the 7MM were approximately 57,000 cases in 2025.

*
According to DelveInsight's analysis, the total number of prevalent cases of ALD in the US in 2025 was nearly 21,000, while diagnosed cases were around 6,000.

*
According to studies cited in the report, ALD affects approximately 1 in 20,000 to 1 in 50,000 individuals worldwide, while newborn incidence is estimated at around 1 in 50,000 births.

*
Leading Adrenoleukodystrophy companies, such as Genetix Biotherapeutics, Minoryx Therapeutics, Viking Therapeutics, Poxel, Neuraxpharm, and others, are developing new Adrenoleukodystrophy treatment drugs that can be available in the Adrenoleukodystrophy market in the coming years.

*
The promising Adrenoleukodystrophy therapies in clinical trials include Leriglitazone (MIN-102), VK0214, PXL065, PXL770, and others.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/adrenoleukodystrophy-market [https://www.delveinsight.com/sample-request/adrenoleukodystrophy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]

Key Factors Driving the Adrenoleukodystrophy Market

Increasing Adoption of Newborn Screening Programs:

Expanding newborn screening programs across multiple regions are enabling earlier diagnosis of ALD, allowing timely MRI monitoring and therapeutic intervention before irreversible neurological damage occurs. Early detection is significantly improving treatment outcomes in patients with cerebral ALD.

Growing Advancements in Gene and Cell-based Therapies:

Gene and cell-based therapies such as SKYSONA are transforming the treatment landscape for patients with early cerebral ALD, especially for individuals lacking a suitable donor for hematopoietic stem cell transplantation (HSCT). The growing success of gene therapy approaches is increasing confidence in disease-modifying treatment strategies.

Rising Focus on Emerging Metabolic-targeted Therapies:

Several investigational therapies targeting metabolic dysfunction, neuroinflammation, mitochondrial pathways, and VLCFA metabolism are being evaluated in clinical trials. Emerging therapies such as Leriglitazone and VK0214 are expected to significantly improve treatment options for adult adrenomyeloneuropathy (AMN) patients.

Adrenoleukodystrophy Competitive Landscape

Several Adrenoleukodystrophy drugs in development include Leriglitazone (MIN-102) (Minoryx Therapeutics and Neuraxpharm), VK0214 (Viking Therapeutics), PXL065 and PXL770 (Poxel), and others.

These candidates target diverse mechanisms such as PPAR- agonism (Leriglitazone), thyroid hormone receptor- activation (VK0214), mitochondrial pyruvate carrier modulation (PXL065), and AMPK activation (PXL770), aiming to reduce VLCFA accumulation, improve mitochondrial metabolism, and slow neurological progression in ALD patients.

Discover more about therapies set to grab major Adrenoleukodystrophy market share @ Adrenoleukodystrophy Treatment Landscape [https://www.delveinsight.com/sample-request/adrenoleukodystrophy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]

Recent Developments in the Adrenoleukodystrophy Market

*
In July 2025, Minoryx Therapeutics and Neuraxpharm announced that the Marketing Authorization Application (MAA) for Leriglitazone (NEZGLYAL) for cerebral ALD was validated by the European Medicines Agency and is currently under CHMP review.

*
In August 2025, the US FDA required updated safety labeling for SKYSONA after reports of hematologic malignancies were observed in treated patients, reinforcing long-term monitoring requirements.

*
In October 2024, Viking Therapeutics announced positive Phase Ib clinical trial results for VK0214 in patients with X-linked ALD, demonstrating significant reductions in VLCFA levels.

*
In December 2022, Poxel announced that PXL065 received Fast Track Designation from the US FDA for adrenomyeloneuropathy associated with X-linked ALD, followed by Orphan Drug Designation in 2023.

What is Adrenoleukodystrophy?

Adrenoleukodystrophy (ALD) is a rare, X-linked genetic neurodegenerative disorder caused by mutations in the ABCD1 gene, resulting in the accumulation of very-long-chain fatty acids (VLCFAs) in the body. The disease progressively damages the brain, spinal cord, and adrenal glands, leading to severe neurological impairment and adrenal insufficiency. ALD presents in multiple phenotypes, including childhood cerebral ALD, adrenomyeloneuropathy (AMN), and Addison disease. Symptoms may include behavioral changes, vision and hearing loss, seizures, impaired motor function, and progressive neurological decline.

Adrenoleukodystrophy Epidemiology Segmentation

The Adrenoleukodystrophy epidemiology section provides insights into the historical and current Adrenoleukodystrophy patient pool and forecasted trends for the leading markets. The Adrenoleukodystrophy market report proffers epidemiological analysis for the study period 2022-2036 in the leading markets, segmented into:

*
Total Prevalent Cases of Adrenoleukodystrophy

*
Total Diagnosed Prevalent Cases of Adrenoleukodystrophy

*
Gender-specific Diagnosed Prevalent Cases of Adrenoleukodystrophy

*
Stage-specific Diagnosed Prevalent Cases of Adrenoleukodystrophy

Scope of the Adrenoleukodystrophy Market Report

*
Therapeutic Assessment: Adrenoleukodystrophy current marketed and emerging therapies

*
Adrenoleukodystrophy Market Dynamics: Key Market Forecast Assumptions of Emerging Adrenoleukodystrophy Drugs and Market Outlook

*
Key Companies: Genetix Biotherapeutics, Minoryx Therapeutics, Viking Therapeutics, Poxel, Neuraxpharm, and others

*
Key Therapies: SKYSONA, Leriglitazone (MIN-102), VK0214, PXL065, PXL770, and others

*
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies

*
Unmet Needs, KOL's views, Analyst's views, Adrenoleukodystrophy Market Access and Reimbursement

To know more about Adrenoleukodystrophy companies working in the treatment market, visit @ Adrenoleukodystrophy Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/adrenoleukodystrophy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]

Table of Contents

*
Adrenoleukodystrophy Market Report Introduction

*
Executive Summary for Adrenoleukodystrophy

*
SWOT Analysis of Adrenoleukodystrophy

*
Adrenoleukodystrophy Patient Share (%) Overview at a Glance

*
Adrenoleukodystrophy Market Overview at a Glance

*
Adrenoleukodystrophy Background and Overview

*
Adrenoleukodystrophy Epidemiology and Patient Population

*
Country-Specific Patient Population of Adrenoleukodystrophy

*
Adrenoleukodystrophy Current Treatment and Medical Practices

*
Adrenoleukodystrophy Unmet Needs

*
Adrenoleukodystrophy Emerging Therapies

*
Adrenoleukodystrophy Market Outlook

*
Country-Wise Adrenoleukodystrophy Market Analysis (2022-2036)

*
Adrenoleukodystrophy Market Access and Reimbursement of Therapies

*
Adrenoleukodystrophy Market Drivers

*
Adrenoleukodystrophy Market Barriers

*
Adrenoleukodystrophy Appendix

*
Adrenoleukodystrophy Report Methodology

*
DelveInsight Capabilities

*
Disclaimer

*
About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=adrenoleukodystrophy-market-is-expected-to-witness-significant-growth-by-2036-owing-to-the-emergence-of-gene-and-metabolictargeted-therapies-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/consulting/due-diligence-services
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.